» Articles » PMID: 26529630

Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants

Abstract

Context: Individualized management, incorporating papillary thyroid cancer (PTC) variant-specific risk, is conceivably a useful treatment strategy for PTC, which awaits comprehensive data demonstrating differential risks of PTC variants to support.

Objective: This study sought to establish the differential clinicopathological risk of major PTC variants: conventional PTC (CPTC), follicular-variant PTC (FVPTC), and tall-cell PTC (TCPTC).

Methods: This was a retrospective study of clinicopathological outcomes of 6282 PTC patients (4799 females and 1483 males) from 26 centers and The Cancer Genome Atlas in 14 countries with a median age of 44 years (interquartile range, 33-56 y) and median follow-up time of 37 months (interquartile range, 15-82 mo).

Results: The cohort consisted of 4702 (74.8%) patients with CPTC, 1126 (17.9%) with FVPTC, and 239 (3.8%) with TCPTC. The prevalence of high-risk parameters was significantly different among the three variants, including extrathyroidal invasion, lymph node metastasis, stages III/IV, disease recurrence, mortality, and the use (need) of radioiodine treatment (all P < .001), being highest in TCPTC, lowest in FVPTC, and intermediate in CPTC, following an order of TCPTC > CPTC ≫ FVPTC. Recurrence and mortality in TCPTC, CPTC, and FVPTC were 27.3 and 6.7%, 16.1 and 2.5%, and 9.1 and 0.6%, corresponding to events per 1000 person-years (95% confidence interval [CI]) of 92.47 (64.66-132.26) and 24.61 (12.31-49.21), 34.46 (30.71-38.66), and 5.87 (4.37-7.88), and 24.73 (18.34-33.35) and 1.68 (0.54-5.21), respectively. Mortality hazard ratios of CPTC and TCPTC over FVPTC were 3.44 (95% CI, 1.07-11.11) and 14.96 (95% CI, 3.93-56.89), respectively. Kaplan-Meier survival analyses showed the best prognosis in FVPTC, worst in TCPTC, and intermediate in CPTC in disease recurrence-free probability and disease-specific patient survival. This was particularly the case in patients at least 45 years old.

Conclusion: This large multicenter study demonstrates differential prognostic risks of the three major PTC variants and establishes a unique risk order of TCPTC > CPTC ≫ FVPTC, providing important clinical implications for specific variant-based management of PTC.

Citing Articles

Comprehensive transcriptomic profiling reveals molecular characteristics and biomarkers associated with risk stratification in papillary thyroid carcinoma.

Yan C, Zheng C, Luo J, Wu X, Meng X, Lv C J Pathol Clin Res. 2025; 11(2):e70022.

PMID: 40001321 PMC: 11860273. DOI: 10.1002/2056-4538.70022.


Comparison of Clinical and Pathological Characteristics of Thyroid Cancer Surgery in the Pandemic Era.

Shafaeipour A, Shirkhoda M, Karami M, Moosaie F, Jalaeefar A, Motiee-Langroudi M Med J Islam Repub Iran. 2024; 38:99.

PMID: 39678773 PMC: 11644028. DOI: 10.47176/mjiri.38.99.


SIX1 expression and its clinicopathological significance: difference between classic and follicular variant papillary thyroid carcinoma.

Khalil E, Issa A, Kamal R Thyroid Res. 2024; 17(1):26.

PMID: 39648214 PMC: 11626750. DOI: 10.1186/s13044-024-00212-9.


Machine Vision-Detected Peritumoral Lymphocytic Aggregates Are Associated With Disease-Free Survival in Patients With Papillary Thyroid Carcinoma.

Monabbati S, Fu P, Asa S, Pathak T, Willis J, Shi Q Lab Invest. 2024; 104(12):102168.

PMID: 39505213 PMC: 11659025. DOI: 10.1016/j.labinv.2024.102168.


Revolutionary multi-omics analysis revealing prognostic signature of thyroid cancer and subsequent in vitro validation of SNAI1 in mediating thyroid cancer progression through EMT.

Jin X, Fu C, Qi J, Chen C Clin Exp Med. 2024; 24(1):127.

PMID: 38869635 PMC: 11176101. DOI: 10.1007/s10238-024-01387-z.


References
1.
Nucera C, Porrello A, Antonello Z, Mekel M, Nehs M, Giordano T . B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci U S A. 2010; 107(23):10649-54. PMC: 2890809. DOI: 10.1073/pnas.1004934107. View

2.
Elsheikh T, Asa S, Chan J, DeLellis R, Heffess C, LiVolsi V . Interobserver and intraobserver variation among experts in the diagnosis of thyroid follicular lesions with borderline nuclear features of papillary carcinoma. Am J Clin Pathol. 2008; 130(5):736-44. DOI: 10.1309/AJCPKP2QUVN4RCCP. View

3.
Czarniecka A, Rusinek D, Stobiecka E, Krajewska J, Kowal M, Kropinska A . Occurrence of BRAF mutations in a Polish cohort of PTC patients - preliminary results. Endokrynol Pol. 2010; 61(5):462-6. View

4.
ONeill C, Bullock M, Chou A, Sidhu S, Delbridge L, Robinson B . BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010; 148(6):1139-45. DOI: 10.1016/j.surg.2010.09.005. View

5.
Chang H, Lin J, Chou S, Chao T, Hsueh C . Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas. Jpn J Clin Oncol. 2006; 36(11):688-93. DOI: 10.1093/jjco/hyl093. View